CG Oncology, Inc. (CGON) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $62.94: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum.
CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). Phase 3 BOND-003 Cohort C enrollment complete with positive data; BLA submission initiated Q4 2025 with FDA PDUFA... Read more
Sell if holding. Engine safety override at $62.94: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.4/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 80d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — CG Oncology, Inc.
Latest news
- Wolfe Research Initiates Coverage On CG Oncology with Peer Perform Rating — benzinga May 19, 2026 neutral
- HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $100 Price Target — benzinga May 18, 2026 positive
- CG Oncology Reports First Results From CORE‑008 Cohort CX Phase 2 Trial — benzinga May 15, 2026 positive
- Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82 — benzinga May 14, 2026 positive
- JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $96 — benzinga May 11, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $62.94: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 2.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $60.90. Score 5.4/10, moderate confidence.
Take-profit target: $78.55 (+24.8% upside). Prior stop was $60.90. Stop-loss: $60.90.
Quality below floor (1.8 < 4.0).
CG Oncology, Inc. trades at a P/E of N/A (forward -23.3). TrendMatrix value score: 7.5/10. Verdict: Sell.
21 analysts cover CGON with a consensus score of 4.2/5. Average price target: $90.
What does CG Oncology, Inc. do?CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene, an oncolytic immunotherapy...
CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). Phase 3 BOND-003 Cohort C enrollment complete with positive data; BLA submission initiated Q4 2025 with FDA PDUFA date of July 17, 2026; Phase 3 PIVOT-006 (intermediate-risk NMIBC) enrollment complete.